GeoVax Labs Inc (GOVX) Quote

Who else has $400 million in funding

GOVX..................................https://stockcharts.com/h-sc/ui?s=GOVX&p=W&b=5&g=0&id=p86431144783

The government will also provide around $343M for a clinical research organization to conduct the clinical trial. Under the agreement, BARDA will award GeoVax up to $45M for the manufacturing of clinical materials and support for the Phase 2b study

Currently, the FDA has approved two mRNA COVID-19 vaccines, Pfizer (PFE) and BioNTech’s (BNTX) Comirnaty and Moderna’s (MRNA) Spikevax.

GOVX under $3

GOVX.......................................https://stockcharts.com/h-sc/ui?s=GOVX&p=W&b=5&g=0&id=p86431144783

Looking Good!

Looks like a flagger

GOVX higher highs higher lows
I think that run was due in part to the pandemic rally in 20-21
Monkey pox cases have been on the increase lately but no where close to epidemic levels
You pays yore monies and you takes yore chances

pretty 5min

i think up

Monk, do you think GOVX has a chance at obtaining those previous highs in the $50 plus ranges if those funding numbers take place?

GOVX................................https://stockcharts.com/h-sc/ui?s=GOVX&p=W&b=5&g=0&id=p86431144783

Let’s Go!!

GOVXW .20 not mad alligator out at all.15

Nice Day!

FINTEL: The average one-year price target for GeoVax Labs (NasdaqCM:GOVX) has been revised to 77.78 / share. This is an increase of 1,170.83% from the prior estimate of 6.12 dated January 16, 2024.
The price target is an average of many targets provided by analysts. The latest targets range from a low of 5.05 to a high of 126.00 / share. The average price target represents an increase of 3,451.37% from the latest reported closing price of 2.19 / share.

"After a while, Crocodile!" (I think that was part of a Pre-Columbian SONG LYRIC, somewhere??)

Warrants Selling .08s for .15 before the herd does ..catch you later crocodile lol

You too, Bro??

OFF TODAY!

GOVX (Warrants): THANKS for the heads-up!!! (Basically OFF today, but just now tossing a 'starter package' at the Warrants here, for my personal 'amusement'; and fret not, if I 'lose-my-shirt', I WON'T sissy-punk cry about it, Homeboy!!)

$4s back and warrants are cheaper now .06

Go $GOVX

$GOVX
$GOVX Strong mover today..with a test of the 200 day MA at $4.34 well within reach.. pic.twitter.com/wnnzoVjyBp— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) June 24, 2024

GOVX.....................https://stockcharts.com/h-sc/ui?s=GOVX&p=W&b=5&g=0&id=p86431144783

GOVXW: Hey, TW, aren't we both simply delighted that we grabbed $10K worth of these lovely WARRANTS on Monday of this week!!!! On-the-CHEAP!!!! And we both dumped it all about 1-hour ago, when our Warrants hit 2,225% GREEN!!!! Are we two GENIUS traders, or what, DUDE???!!!

Why not ? look at that government funding $400million GOVX will be in $4s when they let it go

GOVXW( Warrants): Have now left our Galaxy!!!

$GOVX time!

Uncle Sam $343 million and $45 million funding . Shorts running for the hills still. Shares of GeoVax (NASDAQ:GOVX) shot up 50% in mid-afternoon trading Tuesday amid news that the US government plans to fund a Phase 2b study of the company's next-generation COVID-19 vaccine.

Under the agreement, BARDA will award GeoVax up to $45M for the manufacturing of clinical materials and support for the Phase 2b study. The government will also provide around $343M for a clinical research organization to conduct the clinical trial.

Currently, the FDA has approved two mRNA COVID-19 vaccines, Pfizer (PFE) and BioNTech’s (BNTX) Comirnaty and Moderna’s (MRNA) Spikevax.




GEO-CM04S1 is currently being evaluated in three ongoing Phase 2 clinical trials:

As a primary vaccine in immunocompromised patients (with hematologic cancers receiving cell transplants or CAR-T therapy). ClinicalTrials.gov Identifier: NCT04977024. A recent presentation of unpublished data from the open-label portion of the trial indicates that GEO-CM04S1 is highly immunogenic in these patients, inducing both antibody responses, including neutralizing antibodies, and T cell responses.
As a booster vaccine in immunocompromised patients with chronic lymphocytic leukemia (CLL), a recognized high-risk group for whom current mRNA vaccines and monoclonal antibody (MAb) therapies appear inadequate relative to providing protective immunity. ClinicalTrials.gov Identifier: NCT05672355.
As a booster vaccine for healthy patients who have previously received the Pfizer or Moderna mRNA vaccine. This trial was fully enrolled in September 2023 and final results are expected in Fourth Quarter 2024, reflecting a 12-month tracking of study patients. ClinicalTrials.gov Identifier: NCT04639466.
About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation Covid-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized Covid-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable Covid-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.

Wish I knew but I like the ride up.

What leaked?

GOVX new 52 week low

GOVX new 52 week low

GOVX new 52 week lo

$GOVX bottom bio recent r/s 2.48M float with $3.54 cash per share and warrants at $6.21 CEO and CFO bought at these levels this month + 13G of 9.99% from 14/02/24

''GeoVax to Present at the 2024 BIO CEO & Investor Conference at February 26, 2024, 4:15 pm ET'' pic.twitter.com/8sXy5x4gpa— STOCKS Gambino (@StocksGambino) February 26, 2024

GOVX new 52 week low

GOVX

GOVX new 52 week low

pure scam

GOVX new week low

GOVX: effective Jan. 31,2024 a one for 15 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

they've been trying for weeks to pump up the price before the R/S, but it didn't fool anyone.

Interesting to see the SP here when the dust settles after the R/S.

Will average down when it hits .05 again

GOVX new 52 week low

GOVX new 52 week low

GOVX new 52=week low

GOVX new 52 week low

Merry Christmas $$$$$$$$

Are you surprised?
This is a R/S dump stock.
The only ones that benefit from holding this stock are the crafty/lucky peeps or the insiders.
How long before the next R/S makes this stock look attractive to investors that don't know any better than to look past the hype?